In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Partecke, Ivo L ^a   Kaeding, André ^a   Sendler, Matthias ^a   Albers, Nele ^a   Kühn, Jens P ^a   Speerforck, Sven ^a   Roese, Sebastian ^a   Seubert, Florian ^a   Diedrich, Stephan ^a   Kuehn, Sandra ^a   Weiss, Ulrich F ^a   Mayerle, Julia ^a   Lerch, Markus M ^a   Hadlich, Stefan ^a   Hosten, Norbert ^a   Heidecke, Claus D ^a   Puls, Ralf ^a   von Bernstorff, Wolfram ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE; GADOMER; GADOMER 17; GADOXETIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HISTOPATHOLOGY; IMAGE ANALYSIS; IN VIVO STUDY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOTOPIC TRANSPLANTATION; PANCREAS TUMOR; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BLOOD FLOW; C57BL MOUSE; DISEASE MODEL; HUMAN; IMAGE ENHANCEMENT; LIVER TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY; RADIOGRAPHY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMAGE ENHANCEMENT; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 79251557485     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-40     Document Type: Article

References (42)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7-33. 10.3322/canjclin.50.1.7, 10735013.
2. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. A white paper: the product of a pancreas cancer think tank. Cancer Res 2001, 61:4923-4932.
3. Robert-Koch-Institut, die u and e.V. GdeKiD Krebs in Deutschland 2003 - 2004. Häufigkeiten und Trends. Krebs in Deutschland, Bauchspeicheldrüse 2008, 38-42. Berlin, Robert-Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Robert-Koch-Institut, die u and e.V. GdeKiD.
4. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9:395. 10.1186/1471-2407-9-395, 2779818, 19912635.
5. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009, 9:463. 10.1186/1471-2407-9-463, 2808322, 20035626.
6. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363:1049-1057. 10.1016/S0140-6736(04)15841-8, 15051286.
7. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170:793-804. 10.2353/ajpath.2007.060929, 1864878, 17322365.
8. Peiper M, Nagoshi M, Patel D, Fletcher JA, Goegebuure PS, Eberlein TJ. Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Int J Cancer 1997, 71:993-999. 10.1002/(SICI)1097-0215(19970611)71:6<993::AID-IJC15>3.0.CO;2-7, 9185703.
9. Kalinina T, Gungor C, Thieltges S, Moller-Krull M, Penas EM, Wicklein D, Streichert T, Schumacher U, Kalinin V, Simon R, Otto B, Dierlamm J, Schwarzenbach H, Effenberger KE, Bockhorn M, Izbicki JR, Yekebas EF. Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer 2010, 10:295. 10.1186/1471-2407-10-295, 2927995, 20553613.
10. McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC, Huang ZQ, Grizzle WE, Stockard CR, Nash KT, Buchsbaum DJ. KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clin Exp Metastasis 2010, 27:591-600. 10.1007/s10585-010-9349-5, 2975384, 20844932.
11. Snyder CS, Kaushal S, Kono Y, Tran Cao HS, Hoffman RM, Bouvet M. Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2009, 9:106. 10.1186/1471-2407-9-106, 2679761, 19351417.
12. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Schabel FM. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984, 44:717-726.
13. Doi C, Egashira N, Kawabata A, Maurya DK, Ohta N, Uppalapati D, Ayuzawa R, Pickel L, Isayama Y, Troyer D, Takekoshi S, Tamura M. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 2010, 10:67. 10.1186/1471-2407-10-67, 2846883, 20181281.
14. Tuveson DA, Zhu L, Gopinathan A, Willis NA, Kachatrian L, Grochow R, Pin CL, Mitin NY, Taparowsky EJ, Gimotty PA, Hruban RH, Jacks T, Konieczny SF. Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res 2006, 66:242-247. 10.1158/0008-5472.CAN-05-2305, 16397237.
15. Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, French R, Lowy AM, Engleman EG. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res 2010, 16:3684-3695. 10.1158/1078-0432.CCR-09-2384, 20534740.
16. Russel WMS, Burch RL. The Principles of Humane Experimental Technique. 1959, 69-154. London, Methuen.
17. McAuliffe MJ, Lalonde FM, McGarry D, Gandler W, Csaky K, Trus BL. Medical Image Processing Analysis & Visualization In Clinical Research. 2001, 381-386. CBMS, IEEE Computer-Based Medical Systems.
18. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998, 171:941-949.
19. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24:148-154. 10.1007/BF00300234, 2544306.
20. Spencer JA, Ward J, Guthrie JA, Guillou PJ, Robinson PJ. Assessment of resectability of pancreatic cancer with dynamic contrast-enhanced MR imaging: technique, surgical correlation and patient outcome. Eur Radiol 1998, 8:23-29. 10.1007/s003300050331, 9442123.
21. Park HS, Lee JM, Choi HK, Hong SH, Han JK, Choi BI. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 2009, 30:586-595. 10.1002/jmri.21889, 19711405.
22. Luciani A, Parouchev A, Smirnov P, Braga G, Wilhelm C, Gazeau F, Boudechiche L, L'Hermine-Coulomb A, Dagher I, Franco D, Rahmouni A, Hadchouel M, Weber A, Clement O. In vivo imaging of transplanted hepatocytes with a 1.5-T clinical MRI system--initial experience in mice. Eur Radiol 2008, 18:59-69. 10.1007/s00330-007-0750-7, 17917732.
23. Sutton EJ, Henning TD, Pichler BJ, Bremer C, Daldrup-Link HE. Cell tracking with optical imaging. Eur Radiol 2008, 18:2021-2032. 10.1007/s00330-008-0984-z, 18506449.
24. Smirnov P. Cellular magnetic resonance imaging using superparamagnetic anionic iron oxide nanoparticles: applications to in vivo trafficking of lymphocytes and cell-based anticancer therapy. Methods Mol Biol 2009, 512:333-353. full_text, 19347287.
25. Bernsen MR, Moelker AD, Wielopolski PA, van Tiel ST, Krestin GP. Labelling of mammalian cells for visualisation by MRI. Eur Radiol 2010, 20:255-274. 10.1007/s00330-009-1540-1, 19672602.
26. Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T, Ni X, Qin X. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 2009, 9:191. 10.1186/1471-2407-9-191, 2702393, 19534821.
27. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101. 10.1016/j.gde.2004.12.003, 2819733, 15661539.
28. Bottomley PA. In vivo tumor discrimination in a rat by proton nuclear magnetic resonance imaging. Cancer Res 1979, 39:468-470.
29. Pinkernelle JG, Stelter L, Hamm B, Teichgraber U. [Small animal MRI: clinical MRI as an interface to basic biomedical research]. Rofo 2008, 180:505-513.
30. van Gemert-Horsthuis K, Florie J, Hommes DW, Lavini C, Reitsma JB, van Deventer SJ, Stoker J. Feasibility of evaluating Crohn's disease activity at 3.0 Tesla. J Magn Reson Imaging 2006, 24:340-348. 10.1002/jmri.20650, 16786589.
31. Koo V, Hamilton PW, Williamson K. Non-invasive in vivo imaging in small animal research. Cell Oncol 2006, 28:127-139.
32. Schmidt GP, Wintersperger B, Graser A, Baur-Melnyk A, Reiser MF, Schoenberg SO. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest Radiol 2007, 42:449-459. 10.1097/01.rli.0000262089.55618.18, 17507818.
33. Ranefall P, Bidar AW, Hockings PD. Automatic segmentation of intra-abdominal and subcutaneous adipose tissue in 3D whole mouse MRI. J Magn Reson Imaging 2009, 30:554-560. 10.1002/jmri.21874, 19711401.
34. Wang H, Van de Putte M, Chen F, De Keyzer F, Jin L, Yu J, Marchal G, de Witte P, Ni Y. Murine liver implantation of radiation-induced fibrosarcoma: characterization with MR imaging, microangiography and histopathology. Eur Radiol 2008, 18:1422-1430. 10.1007/s00330-008-0904-2, 18343928.
35. Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem 2007, 14:77-91. 10.2174/092986707779313516, 17266569.
36. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. Impact of animal handling on the results of 18F-FDG PET studies in mice. o 2006, 47:999-1006.
37. Nieman BJ, Szulc KU, Turnbull DH. Three-dimensional, in vivo MRI with self-gating and image coregistration in the mouse. Magn Reson Med 2009, 61:1148-1157. 10.1002/mrm.21945, 2694491, 19253389.
38. Grimm J, Potthast A, Wunder A, Moore A. Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. Int J Cancer 2003, 106:806-811. 10.1002/ijc.11281, 12866043.
39. Thalheimer A, Otto C, Bueter M, Illert B, Gattenlohner S, Gasser M, Meyer D, Fein M, Germer CT, Waaga-Gasser AM. The intraportal injection model: a practical animal model for hepatic metastases and tumor cell dissemination in human colon cancer. BMC Cancer 2009, 9:29. 10.1186/1471-2407-9-29, 2648996, 19166621.
40. Cespedes MV, Espina C, Garcia-Cabezas MA, Trias M, Boluda A, Gomez del Pulgar MT, Sancho FJ, Nistal M, Lacal JC, Mangues R. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007, 170:1077-1085. 10.2353/ajpath.2007.060773, 1864873, 17322390.
41. Ishizu K, Sunose N, Yamazaki K, Tsuruo T, Sadahiro S, Makuuchi H, Yamori T. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull 2007, 30:1779-1783. 10.1248/bpb.30.1779, 17827739.
42. He Z, Evelhoch JL, Mohammad RM, Adsay NV, Pettit GR, Vaitkevicius VK, Sarkar FH. Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas 2000, 21:69-76. 10.1097/00006676-200007000-00054, 10881935.